Ralliant Corporation (NYSE:RAL) Announces $0.05 Quarterly Dividend

Ralliant Corporation (NYSE:RAL) announced a quarterly dividend on Thursday, May 7th. Investors of record on Monday, June 8th will be paid a dividend of 0.05 per share on Tuesday, June 23rd. This represents a c) annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 8th.

Ralliant Price Performance

Shares of NYSE:RAL opened at $46.32 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38. Ralliant has a 1 year low of $37.27 and a 1 year high of $57.02. The business has a fifty day simple moving average of $44.26 and a 200 day simple moving average of $47.00. The firm has a market cap of $5.18 billion and a price-to-earnings ratio of 23.63.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to analysts’ expectations of $543.04 million. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. As a group, sell-side analysts predict that Ralliant will post 2.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on RAL. Truist Financial cut their price objective on Ralliant from $62.00 to $49.00 and set a “buy” rating for the company in a report on Friday, February 6th. Barclays cut their price objective on Ralliant from $60.00 to $52.00 and set an “overweight” rating for the company in a report on Monday, February 9th. Zacks Research upgraded Ralliant from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Royal Bank Of Canada cut their price objective on Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday, February 6th. Finally, Oppenheimer cut their price objective on Ralliant from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Ralliant presently has an average rating of “Moderate Buy” and a consensus target price of $50.50.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.